How psychedelic medicines move through clinical trials

Before any new medicine reaches a prescribing clinician, it has to pass through a structured sequence of tests designed to establish whether it is safe, whether it works, and whether its benefits outweigh its risks. For conventional drugs this pathway is well established. For psychedelic compounds such as psilocybin, the same regulatory framework applies, but it introduces unusual methodological challenges that researchers and regulators are still working to solve. Understanding how clinical trials work helps explain why progress in psychedelic medicine, though promising, has been gradual and carefully scrutinised.

The phases of clinical development

Clinical drug development is typically divided into three sequential phases, usually preceded by preclinical laboratory and animal studies. Phase I trials are small — generally a few dozen healthy volunteers, or in some psychedelic studies, patients with the target condition — and focus primarily on safety, tolerability, and how the human body processes the compound. Phase II trials enrol people with the condition being studied, looking for early signals of efficacy and refining protocol parameters. Phase III trials are larger, often involving hundreds of participants across multiple sites, and are designed to confirm efficacy and detect less common adverse effects.

In the psychedelic context, each phase typically includes psychological screening, preparation sessions, a dosing session in a supported setting, and follow-up integration sessions. This package of care is part of what is being tested, not just the molecule, which makes these trials more complex and labour-intensive than most standard drug studies.

Why blinding is so difficult

A central pillar of modern trial design is the randomised, double-blind, placebo-controlled study. Blinding means that neither participants nor researchers know who receives the active drug and who receives the placebo, which guards against expectancy effects and observer bias. With psychedelic compounds, effective blinding is widely acknowledged to be extremely difficult. At doses that produce noticeable subjective effects, participants can almost always tell whether they have received the active substance or an inert placebo.

When participants and therapists become aware of who received what, the trial is said to be functionally unblinded, and the psychological expectancy that many consider central to therapeutic benefit becomes entangled with the drug effect itself. Researchers have tried alternatives — active placebos such as niacin, which produces a brief physical flush, or very low doses of the psychedelic — but none fully replicate the psychedelic experience without giving away the assignment. This challenge is one of the most debated methodological issues in psychedelic research and remains a focus for both trial designers and regulators.

What regulators require before approval

Before a medicine can be approved, regulators such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and South Africa's Health Products Regulatory Authority (SAHPRA) assess the totality of the evidence. Requirements generally include adequate and well-controlled trials demonstrating efficacy, comprehensive safety data, and assurance of manufacturing quality under Good Manufacturing Practice. For psychedelics, regulators have signalled that additional elements may be expected, including clear protocols for the therapeutic setting, training standards for facilitators, and plans for managing risks such as prolonged distress or misuse. The FDA has issued draft guidance acknowledging the unique features of psychedelic drug development, including the need to account for psychoactive effects and the role of the therapeutic context. Approval, where granted, may come with risk management requirements or restricted access schemes.

The South African and global landscape

In South Africa, psilocybin is listed as a Schedule 7 substance under the Medicines and Related Substances Act, meaning it has no recognised medical use and is subject to the highest level of control. Any future medical access pathway would require SAHPRA to reschedule the compound, a process that would depend on the same kind of clinical trial evidence regulators worldwide demand. The Australian Therapeutic Goods Administration (TGA) took a notable step in 2023 by rescheduling psilocybin and MDMA for narrow, psychiatrist-supervised use in specific clinical contexts, though without the full Phase III evidence base that typically precedes approval. That decision attracted both interest and criticism, illustrating the tension between patient demand, early evidence, and the established regulatory pathway. In the United States, the FDA has granted breakthrough therapy designations to certain psilocybin programmes, which accelerates development and review but does not itself constitute approval.

The road from laboratory to approved medicine is deliberately demanding. For psychedelic compounds, the pathway is being navigated with scientific rigour and an awareness that the questions being asked are, in some respects, new. The promise is genuine, but so are the challenges, and the evidence base is still being built.